Acneiform Eruption Induced by Dacomitinib (PF-00299804).
- Author:
Seon Yong PARK
1
;
Dae Hun SUH
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Acne and Rosacea Research Laboratory, Seoul National University Hospital, Seoul, Korea. daehun@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Acneiform eruption;
Chemotherapy;
Dacomitinib;
Epidermal growth factor receptor inhibitor
- MeSH:
Acneiform Eruptions*;
Carcinoma, Non-Small-Cell Lung;
Clindamycin;
Dermatology;
Drug Therapy;
Epidermal Growth Factor;
Humans;
Minocycline;
Skin
- From:Korean Journal of Dermatology
2015;53(4):324-327
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
